BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31587780)

  • 1. Cardiotoxicity of Immune Therapy.
    Ganatra S; Parikh R; Neilan TG
    Cardiol Clin; 2019 Nov; 37(4):385-397. PubMed ID: 31587780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of Contemporary Anticancer Immunotherapy.
    Dal'bo N; Patel R; Parikh R; Shah SP; Guha A; Dani SS; Ganatra S
    Curr Treat Options Cardiovasc Med; 2020; 22(12):62. PubMed ID: 33162729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
    Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
    Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
    Asnani A
    Curr Oncol Rep; 2018 Apr; 20(6):44. PubMed ID: 29644505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicities of novel cancer immunotherapies.
    Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
    Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
    Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
    Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies.
    Gutierrez C; Rajendram P; Pastores SM
    Crit Care Clin; 2021 Jan; 37(1):47-67. PubMed ID: 33190775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.
    Piras L; Zuccanti M; Russo P; Riccio F; Agresti A; Lustri C; Dardani D; Ferrera A; Fiorentini V; Tocci G; Tini Melato G; Volpe M; Barbato E; Battistoni A
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular toxicity of immune therapies for cancer.
    Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
    BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.
    Stein-Merlob AF; Ganatra S; Yang EH
    Heart Fail Clin; 2022 Jul; 18(3):443-454. PubMed ID: 35718418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity danger in immunotherapy.
    Jagielska B; Ozdowska P; Gepner K; Kubala S; Siedlecki JA; Sarnowski TJ; Sarnowska E
    IUBMB Life; 2020 Jun; 72(6):1160-1167. PubMed ID: 32359132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy.
    Brumbaugh AD; Narurkar R; Parikh K; Fanucchi M; Frishman WH
    Cardiol Rev; 2019; 27(2):97-107. PubMed ID: 29912044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
    Cheng F; Loscalzo J
    Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.